5-(5-methyl-3-phenyl-isoxazol-4-ylmethoxy)-pyrazine-2-carboxylic acid isopropylamide | 1159543-71-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-(5-methyl-3-phenyl-isoxazol-4-ylmethoxy)-pyrazine-2-carboxylic acid isopropylamide
• 英文别名: 5-[(5-methyl-3-phenyl-1,2-oxazol-4-yl)methoxy]-N-propan-2-ylpyrazine-2-carboxamide
• CAS: 1159543-71-1
• 化学式: C₁₉H₂₀N₄O₃
• 分子量: 352.393
• InChiKey: VWJDHGXIIIODOF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  90.1
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  5-(5-methyl-3-phenyl-isoxazol-4-ylmethoxy)-pyrazine-2-carboxylic acid 、 异丙胺 以to the title compound (SiO2, heptane:ethyl acetate=90:10 to 60:40, 37 mg, 33%) which was obtained as an off-white solid的产率得到5-(5-methyl-3-phenyl-isoxazol-4-ylmethoxy)-pyrazine-2-carboxylic acid isopropylamide
  参考文献：
  名称：

  Isoxazolo-pyrazine derivatives

  摘要：

  本发明涉及异噁唑-吡嗪衍生物及其药学上可接受的盐，具有亲和力和选择性，可与GABA A α5受体结合位点结合，其制造和包含它们的制药组合物。本发明的化合物是GABAAα5的反向激动剂。本发明还涉及增强认知和治疗认知障碍如阿尔茨海默病的方法。

  公开号：

  US07902201B2

文献信息

• ISOXAZOLO-PYRAZINE DERIVATIVES
  申请人：Buettelmann Bernd

  公开号：US20090143407A1

  公开（公告）日：2009-06-04

  The invention relates to isoxazolo-pyrazine derivatives and their pharmaceutically acceptable salts having affinity and selectivity for the GABA A α5 receptor binding site, their manufacture, and pharmaceutical compositions containing them. The compounds of present invention are inverse agonists of GABA A α5. The invention also relates to methods for enhancing cognition and for treating cognitive disorders like Alzheimer's disease.

  这项发明涉及对GABA A α5受体结合位点具有亲和力和选择性的异噁唑啉-吡嗪衍生物及其药用可接受盐，其制备以及含有它们的药物组合物。本发明的化合物是GABA A α5的反向激动剂。该发明还涉及增强认知和治疗阿尔茨海默病等认知障碍的方法。
• US7618973B2
  申请人：——

  公开号：US7618973B2

  公开（公告）日：2009-11-17
• US7902201B2
  申请人：——

  公开号：US7902201B2

  公开（公告）日：2011-03-08
• [EN] ISOXAZOLO-PYRAZINE DERIVATIVES<br/>[FR] DÉRIVÉS D'ISOXAZOLO-PYRAZINE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2009071464A1

  公开（公告）日：2009-06-11

  The present invention is concerned with isoxazolo-pyrazine derivatives of formula (I) wherein X is O or NH; R1 is phenyl or pyridine-2-yl, wherein the rings may be optionally substituted with one, two or three halo; R2 is H or C1-4alkyl; R3 and R4 each are independently H, optionally substituted C1-7alkyl, optionally substituted C1-7alko.xy, CN, halo, NO2, -C(0)-Ra -C(0)-NRbRc or R3 and R4 together form an optionally substituted annelated benzo ring, or a pharmaceutically acceptable salt thereof, having affinity and selectivity for GABA A α5 receptor binding site, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as cognitive enhancer or for the treatment of cognitive disorders like Alzheimer's disease.